Point-of-care-testing for suspected COVID-19 reduces time to results and may improve infection control, suggesting these tests might have clinical advantages over widely used laboratory PCR methods.

Point-of-care-testing for suspected COVID-19 reduces time to results and may improve infection control, suggesting these tests might have clinical advantages over widely used laboratory PCR methods.

Rapid microbiological point-of-care testing for respiratory tract infections does not reduce overall same-day antibiotic prescribing in primary care, a recent study shows.

LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: ...

Large scale deployment of rapid, low-cost, hand-held point of care testing devices for diagnosing infectious diseases is critical for improving global health. Recent advances in engineering and ...

This presentation will briefly cover point-of-care testing (POCT) from a historical standpoint. (What are we doing and why did we decide to do it this way?) This presentation will incorporate ...

This webinar's emphasis on CLIA quality standards and the integration of Integri-sense Technology within RAPIDPoint® 500e System seeks to illuminate the path toward enhanced quality management at the ...

The global lateral flow assay (LFA) market is projected to grow from USD 10.01 billion in 2024 to USD 15.42 billion by 2030, driven by increasing demand for point-of-care testing and the rising ...